CA2953641C - Novel formulation and method of synthesis - Google Patents

Novel formulation and method of synthesis Download PDF

Info

Publication number
CA2953641C
CA2953641C CA2953641A CA2953641A CA2953641C CA 2953641 C CA2953641 C CA 2953641C CA 2953641 A CA2953641 A CA 2953641A CA 2953641 A CA2953641 A CA 2953641A CA 2953641 C CA2953641 C CA 2953641C
Authority
CA
Canada
Prior art keywords
reaction mixture
facbc
acid
formula
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2953641A
Other languages
English (en)
French (fr)
Other versions
CA2953641A1 (en
Inventor
Knut Richard Dyrstad
Torild Wickstrom
Thanushan RAJANAYAGAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CA2953641A1 publication Critical patent/CA2953641A1/en
Application granted granted Critical
Publication of CA2953641C publication Critical patent/CA2953641C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C07C227/20—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters by hydrolysis of N-acylated amino-acids or derivatives thereof, e.g. hydrolysis of carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2953641A 2014-06-30 2015-06-30 Novel formulation and method of synthesis Active CA2953641C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1411569.5A GB201411569D0 (en) 2014-06-30 2014-06-30 Novel formulation and method of synthesis
GB1411569.5 2014-06-30
PCT/EP2015/064796 WO2016001199A1 (en) 2014-06-30 2015-06-30 Novel formulation and method of synthesis

Publications (2)

Publication Number Publication Date
CA2953641A1 CA2953641A1 (en) 2016-01-07
CA2953641C true CA2953641C (en) 2022-09-13

Family

ID=51410328

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2953641A Active CA2953641C (en) 2014-06-30 2015-06-30 Novel formulation and method of synthesis

Country Status (18)

Country Link
US (1) US11077216B2 (enExample)
EP (2) EP3431460B1 (enExample)
JP (3) JP6997519B2 (enExample)
KR (1) KR102381616B1 (enExample)
CN (1) CN106458785B (enExample)
AU (1) AU2015283054B2 (enExample)
BR (1) BR112016030350B1 (enExample)
CA (1) CA2953641C (enExample)
DK (1) DK3431460T3 (enExample)
ES (1) ES2710073T3 (enExample)
GB (1) GB201411569D0 (enExample)
IL (1) IL249348A0 (enExample)
PL (1) PL3160923T3 (enExample)
PT (1) PT3160923T (enExample)
RU (1) RU2016147507A (enExample)
SG (1) SG11201610883QA (enExample)
TR (1) TR201901460T4 (enExample)
WO (1) WO2016001199A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220001034A1 (en) * 2014-06-30 2022-01-06 Ge Healthcare Limited Novel formulation and method of synthesis
US12181452B2 (en) 2017-09-18 2024-12-31 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
US12180581B2 (en) 2017-09-18 2024-12-31 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
US11709156B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved analytical analysis
US11709155B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
GB201805253D0 (en) 2018-03-29 2018-05-16 Ge Healthcare Ltd Ip Solid phase extraction
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
US11918936B2 (en) 2020-01-17 2024-03-05 Waters Technologies Corporation Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding
WO2022064447A1 (en) 2020-09-24 2022-03-31 Waters Technologies Corporation Chromatographic hardware improvements for the separation of reactive molecules

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1356827A1 (en) 2002-04-24 2003-10-29 Mallinckrodt Inc. Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution
US7993626B2 (en) 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
CN100418585C (zh) 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
GB0422004D0 (en) 2004-10-05 2004-11-03 Amersham Plc Method of deprotection
CA2612187C (en) 2005-06-23 2013-05-07 Emory University Stereoselective synthesis of amino acid analogs for tumor imaging
RU2428415C2 (ru) 2005-11-29 2011-09-10 Нихон Меди-Физикс Ко., Лтд. Соединение-предшественник органического соединения, меченного радиоактивным галогеном
US7897811B2 (en) 2006-05-11 2011-03-01 Nihon Medi-Physics Co., Ltd. Process for production of radioactive fluorine-labeled organic compound
US8790620B2 (en) 2006-12-21 2014-07-29 Nihon Medi-Physics Co., Ltd. Radioactive diagnostic imaging agent
EP2119458B9 (en) 2007-02-13 2013-08-21 Nihon Medi-Physics Co., Ltd. Method for production of radiation diagnostic imaging agent
KR20130132892A (ko) 2010-12-29 2013-12-05 지이 헬쓰케어 리미티드 용리제 용액
GB201117785D0 (en) 2011-10-14 2011-11-30 Ge Healthcare Ltd Improved radiosynthesis method
JP6446268B2 (ja) * 2011-12-21 2018-12-26 ジーイー・ヘルスケア・リミテッド クエン酸緩衝液中の18f−フルシクロビン組成物
GB201205703D0 (en) 2012-03-30 2012-05-16 Ge Healthcare Ltd Synthon composition
GB201214220D0 (en) 2012-08-09 2012-09-19 Ge Healthcare Ltd Radiosynthesis

Also Published As

Publication number Publication date
PL3160923T3 (pl) 2019-06-28
EP3431460A3 (en) 2019-02-20
JP6997519B2 (ja) 2022-02-04
TR201901460T4 (tr) 2019-02-21
AU2015283054B2 (en) 2017-11-23
KR20170027732A (ko) 2017-03-10
PT3160923T (pt) 2019-02-12
EP3431460B1 (en) 2021-02-17
DK3431460T3 (da) 2021-05-10
WO2016001199A1 (en) 2016-01-07
JP2020172518A (ja) 2020-10-22
US11077216B2 (en) 2021-08-03
RU2016147507A3 (enExample) 2019-01-18
CA2953641A1 (en) 2016-01-07
BR112016030350B1 (pt) 2024-01-30
EP3160923A1 (en) 2017-05-03
ES2710073T3 (es) 2019-04-22
JP7657759B2 (ja) 2025-04-07
CN106458785A (zh) 2017-02-22
US20170128597A1 (en) 2017-05-11
RU2016147507A (ru) 2018-07-30
BR112016030350A2 (enExample) 2017-08-22
IL249348A0 (en) 2017-02-28
SG11201610883QA (en) 2017-01-27
JP2022136074A (ja) 2022-09-15
EP3160923B1 (en) 2019-01-02
EP3431460A2 (en) 2019-01-23
JP2017520550A (ja) 2017-07-27
AU2015283054A1 (en) 2016-12-08
NZ727574A (en) 2023-11-24
GB201411569D0 (en) 2014-08-13
CN106458785B (zh) 2020-10-09
KR102381616B1 (ko) 2022-04-01

Similar Documents

Publication Publication Date Title
JP7657759B2 (ja) 新規製剤及び合成方法
EP3766522B1 (en) Automated method for the preparation of 18f-fluciclovine compositions
US10023525B2 (en) Preparation of 18F-fluciclovine
EP2793954B1 (en) 18f-fluciclovine compositions in citrate buffers
AU2014242897B2 (en) Radiolabelling process
US11534494B2 (en) Formulation and method of synthesis
US20220001034A1 (en) Novel formulation and method of synthesis
HK1234386B (en) Novel formulation and method of synthesis
GB2561122A (en) 18F - Fluciclovine compositions in citrate buffers

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200622

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250527

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250527